ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,101.24
-0.29%
US Tech 100
20,256.80
-4.38%
다우존스 지수
44,424.25
-0.32%
Bitcoin
98,494.83
-5.90%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Vir Biotechnology Inc (VIR) 시세

Vir Biotechnology Inc

Vir Biotechnology Inc (VIR)

Vidrala SA
10.63
0.10
(0.95%)
마감 25 1월 6:00AM
15분 지연
10.63
0.00
( 0.00% )
시간외 단일가: 6:56PM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
10.63
매수가
10.20
매도가
10.63
거래량
143
0.00 일간 변동폭 0.00
6.56 52주 범위 14.43
market_cap
1.464B
전일 종가
10.63
개장가
-
최근 거래 시간
63
@
10.31
마지막 거래 시간
18:59:30
재정 규모
-
VWAP
-
평균 볼륨(3m)
2,192,891
발행 주식
137,720,120
배당수익률
-
주가수익률
-2.38
주당순이익(EPS)
-4.47
매출
86.18M
순이익
-615.06M

Vir Biotechnology Inc 정보

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.vir.bio
본부
Wilmington, Delaware, USA
설립됨
-
Vir Biotechnology Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker VIR. The last closing price for Vir Biotechnology was US$10.63. Over the last year, Vir Biotechnology shares have traded in a share price range of US$ 6.56 to US$ 14.43.

Vir Biotechnology currently has 137,720,120 shares in issue. The market capitalisation of Vir Biotechnology is US$1.46 billion. Vir Biotechnology has a price to earnings ratio (PE ratio) of -2.38.

VIR 최신 뉴스

추가 뉴스

Form 8-K - Current report

08 1월 2025
Edgar (US Regulatory)

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors ○ VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage...

08 1월 2025
Business Wire

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on...

18 12월 2024
Business Wire

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs – – Phase 3 ECLIPSE registrational program in chronic hepatitis...

13 12월 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

05 12월 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

03 12월 2024
Edgar (US Regulatory)

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of...

26 11월 2024
Business Wire

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore...

25 11월 2024
Business Wire

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24...

19 11월 2024
Business Wire

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week...

19 11월 2024
Business Wire
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.343.3041788143810.2911.2610.01128728910.52348464CS
43.2644.23337856177.3714.437.22417638411.55297929CS
121.3714.79481641479.2614.436.5621928919.99496385CS
26-0.1-0.93196644920810.7314.436.5614610259.39708661CS
521.6918.9038031328.9414.436.5612789759.62182233CS
156-21.65-67.069392812932.2835.486.56119882516.60870929CS
260-15.3-59.005013497925.93141.016.56122100127.42164023CS

VIR - Frequently Asked Questions (FAQ)

What is the current Vir Biotechnology share price?
The current share price of Vir Biotechnology is US$ 10.63
How many Vir Biotechnology shares are in issue?
Vir Biotechnology has 137,720,120 shares in issue
What is the market cap of Vir Biotechnology?
The market capitalisation of Vir Biotechnology is USD 1.46B
What is the 1 year trading range for Vir Biotechnology share price?
Vir Biotechnology has traded in the range of US$ 6.56 to US$ 14.43 during the past year
What is the PE ratio of Vir Biotechnology?
The price to earnings ratio of Vir Biotechnology is -2.38
What is the cash to sales ratio of Vir Biotechnology?
The cash to sales ratio of Vir Biotechnology is 16.99
What is the reporting currency for Vir Biotechnology?
Vir Biotechnology reports financial results in USD
What is the latest annual turnover for Vir Biotechnology?
The latest annual turnover of Vir Biotechnology is USD 86.18M
What is the latest annual profit for Vir Biotechnology?
The latest annual profit of Vir Biotechnology is USD -615.06M
What is the registered address of Vir Biotechnology?
The registered address for Vir Biotechnology is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Vir Biotechnology website address?
The website address for Vir Biotechnology is www.vir.bio
Which industry sector does Vir Biotechnology operate in?
Vir Biotechnology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
JGAurora Mobile Ltd
US$ 18.00
(199.40%)
2.38M
ONCOOnconetix Inc
US$ 0.86
(79.17%)
31.61M
CDZIPCadiz Inc
US$ 28.84
(59.96%)
2
WMPNWilliam Penn Bancorporation
US$ 19.66
(58.55%)
57
HWHHWH International Inc
US$ 0.4372
(51.96%)
17.76M
DSGNDesign Therapeutics Inc
US$ 2.00
(-59.76%)
187
ATLOAmes National Corporation
US$ 7.15
(-59.74%)
45
NODKNI Holdings Inc
US$ 6.01
(-58.58%)
7
FRAFFranklin Financial Services Corporation
US$ 22.00
(-34.01%)
416
SLNGStabilis Solutions Inc
US$ 5.00
(-31.97%)
201
ONCOOnconetix Inc
US$ 0.86
(79.17%)
31.61M
HWHHWH International Inc
US$ 0.4372
(51.96%)
17.76M
TVGNTevogen Bio Holdings Inc
US$ 2.035
(50.74%)
17.54M
NVDANVIDIA Corporation
US$ 125.70
(-11.86%)
16.37M
ACONAclarion Inc
US$ 0.0385
(-29.87%)
7.74M

VIR Discussion

게시물 보기
Monksdream Monksdream 1 월 전
VIR under $8
👍️0
DewDiligence DewDiligence 3 월 전
VIR reports 3Q24 results—9/30/24 cash=$1.19B:

https://www.businesswire.com/news/home/20241031806056/en
👍️0
Monksdream Monksdream 3 월 전
VIR under $10
👍️0
TheFinalCD TheFinalCD 6 월 전
https://x.com/NuntioBot/status/1819101232079786025

https://finviz.com/quote.ashx?t=VIR&p=d#google_vignette

Message in reply to:
VIR pares pipeline—reduces workforce 25%:

https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Reports-Second-Quarter-2024-Financial-Results-and-Announces-Strategic-Restructuring-to-Prioritize-Clinical-Stage-Pipeline-Opportunities/default.aspx

VIR has terminated its programs in flu, COVID, and T cell-based viral vectors.

VIR also announced a collaboration with SNY to develop T-cell engagers (https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx ), but financial terms of the collaboration were not disclosed.


2Q24 CC slides:
https://s203.q4cdn.com/628578897/files/doc_presentations/2024/Jul/Vir-Corporate-Presentation_Q2-2024.pdf
👍️0
DewDiligence DewDiligence 6 월 전
VIR pares pipeline—reduces workforce 25%:

https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Reports-Second-Quarter-2024-Financial-Results-and-Announces-Strategic-Restructuring-to-Prioritize-Clinical-Stage-Pipeline-Opportunities/default.aspx

VIR has terminated its programs in flu, COVID, and T cell-based viral vectors.

VIR also announced a collaboration with SNY to develop T-cell engagers (https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx ), but financial terms of the collaboration were not disclosed.


2Q24 CC slides:
https://s203.q4cdn.com/628578897/files/doc_presentations/2024/Jul/Vir-Corporate-Presentation_Q2-2024.pdf
👍️0
Monksdream Monksdream 6 월 전
VIR under $11
👍️0
Monksdream Monksdream 7 월 전
VIR under $10
👍️0
DewDiligence DewDiligence 8 월 전
VIR +18% on phase-2 HDV data at EASL:

https://finance.yahoo.com/news/tobevibart-monotherapy-combination-therapy-elebsiran-093000369.html

Note: HDV is a subset of HBV insofar as HDV resides within HBV’s capsid.
👍️0
DewDiligence DewDiligence 9 월 전
VIR 1Q24 CC transcript:

https://finance.yahoo.com/news/vir-biotechnology-inc-nasdaq-vir-170535096.html
👍️0
Monksdream Monksdream 9 월 전
VIR still reversing off the recent 52 week low
👍️0
DewDiligence DewDiligence 9 월 전
VIR reports 1Q24 results—3/31/24 cash=$1.51B(!):

https://www.businesswire.com/news/home/20240502260564/en

VIR re-iterated guidance for 2024 operating expenses of $650-680M.

CC slides:
https://investors.vir.bio/files/doc_financials/2024/q1/Vir-Corporate-Presentation_Q1-2024.pdf
👍️0
Monksdream Monksdream 9 월 전
VIR under $10
👍️0
DewDiligence DewDiligence 9 월 전
VIR adds two luminaries to BoD:

https://www.businesswire.com/news/home/20240418098064/en

The capsule bios in the PR speak for themselves.
👍️0
DewDiligence DewDiligence 11 월 전
VIR 4Q23 CC transcript:

https://finance.yahoo.com/news/q4-2023-vir-biotechnology-inc-185403667.html
👍️ 1
DewDiligence DewDiligence 11 월 전
VIR 4Q23 CC slides:

https://investors.vir.bio/files/doc_presentations/2024/02/22/Vir-Corporate-Presentation_Q4-2023.pdf
👍️0
DewDiligence DewDiligence 11 월 전
VIR reports 4Q23 results—issues 2024 expense guidance:

https://www.businesswire.com/news/home/20240222740501/en

12/31/23 cash was $1.63B, after burning $108M during 4Q23.

2024 guidance for SG&A + R&D GAAP expenses is $650-680M.

At the current share price, VIR has an enterprise value of roughly negative $200M.
👍️0
DewDiligence DewDiligence 11 월 전
VIR’s CMO left the company, which explains the exercise-and-hold transaction from January in the post I'm replying to:

https://finance.yahoo.com/news/vir-biotechnology-announces-dr-phil-213000676.html

Note: The above was issued on 2/20/24.
👍️0
DewDiligence DewDiligence 11 월 전
GSK, VIR terminate flu collaboration inked in 2021:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001706431/000162828024006346/vir-20240221.htm

This outcome is not surprising outcome insofar as the phase-2 trial of VIR-2484, the lead compound of the collaboration, was a failure ( #msg-172395320).
👍️0
DewDiligence DewDiligence 1 년 전
VIR’s CMO exercised and held ~$800K of stock yesterday:

https://www.sec.gov/Archives/edgar/data/1706431/000162828024000169/xslF345X05/wk-form4_1704311270.xml

The options in question did not expire until 2027-2028.
👍️0
DewDiligence DewDiligence 1 년 전
VIR cuts workforce 12%:

https://www.businesswire.com/news/home/20231213396441/en

It’s bizarre to see belt-tightening by a company with $1.7B of net cash (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001706431/000162828023036702/vir-20230930.htm#i4ba948c416a6412b946073491455ca74_19 ), but it’s probably the right thing to do inasmuch as the stock’s EV is deeply negative.
👍️0
harry crumb harry crumb 1 년 전
Nice move today
👍️0
DewDiligence DewDiligence 2 년 전
VIR -45% on phase-2 failure in influenza:

https://finance.yahoo.com/news/vir-biotechnology-announces-topline-data-120000102.html Vir Biotechnology…today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. Why such a steep selloff? One reason is that VIR has tended to present itself to investors as all-powerful and all-knowing, which is perhaps a consequence of having George Scangos as (ex)CEO and having raised a huge amount of capital based on management’s reputation.
👍️0
DewDiligence DewDiligence 2 년 전
VIR starts 4-drug phase-2 HBV trial:

https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html

The four drugs are: VIR-2218, a siRNA; VIR-3434, a mAb; PEG-IFN; and a (generic) nucleoside.

A separate phase-2 trial (VIR calls it a “subprotocol”) will test VIR-3434 and a nuke, with and without VIR-2218, in patients who are chronic inactive carriers of the HBV virus. I'm unclear as to whether this second trial is for research purposes or for an addressable commercial market.
👍️0
DewDiligence DewDiligence 2 년 전
48w VIR-2219 +peg-IFN—>31% HBs seroconverion:

https://www.globenewswire.com/news-release/2022/11/06/2549180/0/en/Vir-Biotechnology-Presents-New-Data-Evaluating-the-Potential-for-VIR-2218-and-VIR-3434-to-Achieve-a-Functional-Cure-for-Chronic-Hepatitis-B-Virus-HBV-Infection.html

The 31% figure is impressive insofar as peg-IFN by itself has a 48w seroconversion rate of only 5-10%. Of course, a 48w regimen of VIR-2219 + peg-IFN won’t be any easier to tolerate than 48w of peg-IFN monotherapy, so this regimen is still far from the ultimate answer for treating chronic HBV.

VIR has started testing the triple combination of VIR-2219 (siRNA) + VIR-3434 (mAb) + peg-IFN; initial data are expected in 2H23.
👍️0
DewDiligence DewDiligence 3 년 전
VIR EASL presentations:

https://www.globenewswire.com/news-release/2022/06/25/2469082/0/en/Vir-Biotechnology-Announces-New-Clinical-Data-From-its-Broad-Hepatitis-B-Program.html

No CC.
👍️0
DewDiligence DewDiligence 3 년 전
VIR HBV webcast slides:

https://investors.vir.bio/static-files/7ece44c3-0585-47af-81b4-2199889d6934
👍️0
DewDiligence DewDiligence 3 년 전
VIR -14% on amended Sotrovimab EUA due to Omicron BA.2 variant:

https://finance.yahoo.com/news/us-food-drug-administration-revises-200400156.html GlaxoSmithKline plc and Vir Biotechnology…today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by Vir, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant.

GSK and Vir are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion. This PR was issued after the close, but the market apparently got wind of the FDA decision about 3:45pm ET.
👍️0
DewDiligence DewDiligence 3 년 전
VIR 4Q21 results:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5 million in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.
👍️0
DewDiligence DewDiligence 3 년 전
VIR’s 2022 HBV newsflow:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html In 2022, the Company expects data readouts from multiple trials evaluating VIR-2218 and VIR-3434:

• Initial data from the first cohorts of Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial of VIR-2218 in combination with VIR-3434, are expected in the first half of 2022.

• Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-alpha are expected in the first half of 2022.

• Additional data from the Phase 1 monotherapy trial of VIR-3434 are expected in the first half of 2022.

• The Company’s collaborator, Brii Biosciences, continues to lead the Phase 2 trial evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection. Initial data are expected in the second half of 2022. Evidently, there will not be a 2022 readout from the phase-2 trial testing combinations of VIR-2218, GILD’s GS-9688, Vemlidy (TAF), and Opdivo (#msg-167061759, #msg-160854272, #msg-167063133).
👍️0
rwwest rwwest 3 년 전
Up so far on another Biotech down day
Seems like a good omen.
👍️0
DewDiligence DewDiligence 3 년 전
VIR slide set from JPM:

https://investors.vir.bio/static-files/7ecf45fb-6918-4cf8-9a02-b8c12183ca4f
👍️0
DewDiligence DewDiligence 3 년 전
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.
👍️0
HokieHead HokieHead 3 년 전
Loaded again. After omicron news all weekend this will be the next MRNA biotech. $75+ by years end for starters imo.
👍️0
HokieHead HokieHead 3 년 전
In $46, omicron play.
👍️0
DewDiligence DewDiligence 4 년 전
VIR starts HBV_combination_trial_of_ VIR-2218 and VIR-3434:

https://finance.yahoo.com/news/vir-biotechnology-initiates-phase-2-123000780.html The multi-center, open-label Phase 2 trial is designed to evaluate the safety, tolerability and efficacy of the combination of VIR-2218 and VIR-3434 in approximately 90 adult patients (ages 18 to 65) with chronic HBV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Both VIR-2218 and VIR-3434 will be administered via subcutaneous injection at varying dose levels over the course of the trial for a treatment period ranging from four to 20 weeks, and a follow-up period of up to 116 weeks, depending on the dosing cohort.

…VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens. VIR-3434 is an investigational HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 “vaccinal mutation,” allowing it to potentially function as a therapeutic T cell vaccine against HBV. See #msg-164593550, #msg-161217289, and #msg-164599741 for related info.
👍️0
DewDiligence DewDiligence 4 년 전
VIR -6% on VIR-2218 and VIR-3434 monotherapy data presented at EASL:

https://finance.yahoo.com/news/vir-biotechnology-presents-clinical-data-125000851.html

CC to discuss these data with investment community at 11am ET.
👍️0
level42 level42 4 년 전
"profound efficacy." Vir Biotechnology and GSK plan to seek emergency use authorization for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients.


Based on these positive results, Vir and GlaxoSmithKline intend to request Emergency Use Authorization (EUA) for VIR-7831 from the U.S. Food and Drug Administration (FDA) and other international regulators.

"We are pleased that this unique monoclonal antibody was able to bring such a profound benefit to patients," GlaxoSmithKline chief scientific officer Dr. Hal Barron said. "We look forward to the possibility of making VIR-7831 available to patients as soon as possible."
👍️0
interloper interloper 4 년 전
Too high too fast. Very typical price movement. I you think your gonna ride a rocket to the moon you better be ready when the booster fuel runs out.
👍️0
dealerschool2006 dealerschool2006 4 년 전
why is VIR coming back down???
👍️0
rtrstock rtrstock 4 년 전
Huge disappointment.

This could go back to under 20.00 pps

Should have sold at 140.00

This stock price is just based on hype, the collapse is the reality of things.

👍️0
CatBirdSeat CatBirdSeat 4 년 전
Two New Rockships Taking Off After VIR

Behold! FNMA & FMCC

Ka Ching ! Baby! $$$$
👍️0
rtrstock rtrstock 4 년 전
I Should have sold at 140.00

Now it's in a death spiral.

Robinhood shows this listing at a completely different price than ihub.
👍️0
Srhogan1984 Srhogan1984 4 년 전
Full of crap haha
👍️0
ClayTrader ClayTrader 4 년 전
* * $VIR Video Chart 01-26-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Srhogan1984 Srhogan1984 4 년 전
Sounds like a short to me. You need a bog squeeze? Haha
👍️0
DewDiligence DewDiligence 4 년 전
Today's move is somewhat scary in the context of #msg-160142077.
👍️0
DewDiligence DewDiligence 4 년 전
VIR—(+40% undeservedly, IMO)—on_interim_phase-1_data_for VIR-3434_in_HBV:

https://www.globenewswire.com/news-release/2021/01/26/2164220/0/en/Initial-Data-from-Ongoing-Phase-1-Trial-of-VIR-3434-for-Chronic-Hepatitis-B-Virus-Infection-Demonstrates-Significant-and-Rapid-Reduction-in-Hepatitis-B-Surface-Antigen.html

The mean reduction in HBsAg (n=6) was 1.3 logs after 8 days. That’s not bad, but neither is it a knock-your-socks-off result. Monotherapy is unlikely to generate a functional cure in HBV, no matter how potent the agent may be against HBsAg.

VIR-3434 is a monoclonal antibody and is VIR’s second HBV agent in the clinic; the first is VIR-2218, an RNAi agent (#msg-155042587).
👍️0
DewDiligence DewDiligence 4 년 전
Not really. It's just a phase-2 trial, not a full-fledged partnership.
👍️0
DewDiligence DewDiligence 4 년 전
GILD, VIR collaborate on phase-2 HBV trial:

https://www.businesswire.com/news/home/20210112005578/en The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. I.e., no cash is changing hands between the two companies.
👍️0
Srhogan1984 Srhogan1984 4 년 전
Huge news!
👍️0

최근 히스토리

NASDAQ
VIR
Vir Biotechnology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유